Shares of EXACT Sciences (EXAS) are poised for a major break-out upon colorectal cancer (CRC) screening guidelines in November which will bring its $107 million market cap more in line (or above) peers APPY ($377 million) & SQNM ($425 million). I expect EXAS to end the year around the $15 - $20 level with guidelines inclusion, positive V2 clinical trial results demonstrating better sensitivity than previous 88%, and clarity on the Company's strategy for an FDA-approved version of its sDNA CRC screening test. Beyond these catalysts, EXACT is expected to sign a lucrative partnering agreement (e.g. $40 million upfront + mid-teens royalties) for its FDA-approved test & receive Medicare reimbursement in the 1Q/2Q08.
October 25, 2007
Did you like this article?
Submitted By 
's
